2005, Food and Drug Administration, Leads and Safety

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2005

Food and Drug Administration

Leads

Safety

The future of medical cannabis development in Europe

European Pharmaceutical Review

JULY 13, 2023

3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful.

Medical

Medical Food and Drug Administration Pharmacology Medicine

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline.

Food and Drug Administration

Food and Drug Administration Safety Patients Leads

Pharma Rep Focus

The future of medical cannabis development in Europe

Paving the way for anti-Abeta active immunotherapy

Stay Connected